Antiplatelet Secondary Prevention International Randomised Trial After

Status Active, not recruiting

Clinical Trial Summary

ASPIRING is an investigator-led, multicentre, prospective, randomised, open-label, blind outcome (PROBE), parallel group, clinical trial. The pilot phase will explore the feasibility of conducting a trial of starting antiplatelet monotherapy versus avoiding antiplatelet therapy for reducing all serious vascular events for adults surviving symptomatic stroke due to spontaneous intracerebral haemorrhage (ICH). The pilot phase will involve ~120 patients at ~30 hospitals in China, Australia and New Zealand.

Clinical Trial Description

The participant eligibility criteria specifically identify adults with history of symptomatic spontaneous ICH. Randomisation occurs if a participant and their doctor are uncertain about whether to start or avoid antiplatelet monotherapy at least 24 hours after ICH symptom onset. The intervention is a pragmatic policy of starting antiplatelet monotherapy (one antiplatelet drug available in local standard clinical practice, chosen by patient's physician pre-randomisation). The control group adopts a policy of avoiding antiplatelet therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04522102
Study type	Interventional
Source	The George Institute for Global Health, China
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	September 3, 2021
Completion date	October 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05089331` - ROSE-Longitudinal Assessment With Neuroimaging
Recruiting	`NCT03605381` - MORbidity PRevalence Estimate In StrokE
Terminated	`NCT04178746` - PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
Not yet recruiting	`NCT03956485` - Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT).
Enrolling by invitation	`NCT02920645` - Multicenter Validation of the AVICH Score	N/A
Recruiting	`NCT02625948` - Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign	Phase 2
Completed	`NCT02478177` - Addressing Real-world Anticoagulant Management Issues in Stroke
Completed	`NCT01971359` - Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study	N/A
Completed	`NCT01261091` - Early Tracheostomy in Ventilated Stroke Patients	N/A
Terminated	`NCT00990509` - Albumin for Intracerebral Hemorrhage Intervention	Phase 2
Completed	`NCT00716079` - The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial	N/A
Recruiting	`NCT00222625` - rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets	Phase 2
Recruiting	`NCT05095857` - The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury	Phase 4
Recruiting	`NCT04548596` - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Not yet recruiting	`NCT06429332` - International Care Bundle Evaluation in Cerebral Hemorrhage Research	Phase 4
Recruiting	`NCT05492474` - Cranial Ultrasound for Prehospital ICH Diagnosis	N/A
Not yet recruiting	`NCT05502874` - Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage
Recruiting	`NCT04604587` - MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA	Phase 3
Recruiting	`NCT05504941` - Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage	N/A
Not yet recruiting	`NCT05066620` - Chinese Herbal Medicine in Acute INtracerebral Haemorrhage (CHAIN) Trial	Phase 3

Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms